Trueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810 : vimarsana.com

- TTX-810 is designed for rapid clearance to circumvent mechanism-based risks of MCL1 inhibition - High potency affords robust anti-tumor effects whilst preserving cardiomyocyte viability - Trueline

Related Keywords

Emily Wong , Michael Serrano Wu , Gewinn Nur , Chloe Kamps , Ulla Rauh , Anji Pharmaceuticals , Anji Pharmaceuticals Inc , Broad Institute Of Harvard , Bayer Pharmaceuticals , Trueline Therapeutics Inc , Therapeutics Inc , Broad Institute , Trueline Therapeutics , Chief Scientific Officer , Anji Pharma , Dougall Advisors , Trueline , Herapeutics , Nnounces , Ompletion , Nabling , Tudies , Cl1 , Nhibitor ,